Table 2.
Characteristics of patients according to resistive index (RI) value
| RI<0.8 (n= 28) | RI≥0.8 (n= 26) | P | |
|---|---|---|---|
| Sex (male) | 20 (71.4) | 18 (69.2) | 1.000 |
| Age (y) | 55.25±13.55 | 66.15±9.70 | 0.001 |
| Medical history | |||
| DM | 9 (32.1) | 22 (84.6) | <0.001 |
| HTN | 26 (92.9) | 23 (88.5) | 0.663 |
| IHD | 3 (10.7) | 10 (38.5) | 0.026 |
| CVA | 5 (17.9) | 6 (23.1) | 0.741 |
| PAD | 1 (3.6) | 4 (15.4) | 0.184 |
| Baseline renal function | |||
| Creatinine (mg/dL) | 1.94±1.00 | 1.76±0.64 | 0.458 |
| RUP/Cr (g/g) | 3.51±3.36 | 4.20±2.81 | 0.584 |
| eGFR (mL/min/1.73 m2) | 46.7±24.0 | 43.7±16.7 | 0.606 |
| Right kidney size (cm) | 10.29±1.25 | 10.57±1.85 | 0.359 |
| Systemic Factor | |||
| Hb (g/dL) | 12.47±2.37 | 11.38±1.88 | 0.070 |
| Albumin (g/dL) | 3.98±0.61 | 3.89±0.50 | 0.570 |
| SBP (mmHg) | 138.3±22.7 | 140.8±32.1 | 0.739 |
| DBP (mmHg) | 85.9±12.0 | 70.6±16.1 | <0.001 |
| PP (mmHg) | 52.3±18.9 | 70.1±20.7 | 0.002 |
| Cardiac EF | 57.2±8.7 | 53.5±11.7 | 0.320 |
| Medication | |||
| ACE inhibitor (%) | 2(7.1) | 2 (7.7) | 1.000 |
| ARB | 19 (67.9) | 19 (73.1) | 0.770 |
| ACE inhibitor+ARB | 7 (25.0) | 5 (19.2) | 0.747 |
| Diuretics | 11 (39.3) | 19 (73.1) | 0.016 |
| RI | 0.70±0.05 | 0.86±0.04 | <0.001 |
| ESV | 0.26±0.82 | 0.28±060 | 0.411 |
| EDV | 0.09±0.66 | 0.04±0.16 | 0.009 |
| AKI | 2 (7.1) | 10 (38.5) | 0.008 |
Data are expressed as n (%) or mean ± SD.
ACE inhibitor, angiotensin converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; Combination, ACE inhibitor and ARB combination; Cr, creatinine; CVA, cerebro-vascular accident; DBP, diastolic blood pressure; DM, diabetes mellitus; EDV, end diastolic velocity; EF, ejection fraction; eGFR, glomerular filtration rate estimated by the modified modification of diet in renal disease equation; ESV, end systolic velocity; Hb, hemoglobin; HTN, hypertension; IHD, ischemic heart disease; PAD, peripheral artery disease; PP, pulse pressure; RUP, random urine protein; SBP, systolic blood pressure.